Risteys ·

OMOP concept ID	Test name	Measurement unit (harmonized unit)	N people	N records	Missing measurement value	Harmonized value distribution
42870560	us-tsh	mU/l (mu/l)	407	407	0.74%
42870560	us-tsh	— (—)	75	75	100.00%	Distribution not available
42870560	us-tsh	mU/l______ (mu/l)	7	7	0.00%	Distribution not available

LabWAS

N Cases

N Controls

-log₁₀(p)

cases

controls

cases

controls

unit

-log₁₀(p)

N cases

N controls

Persons with potential health hazards related to communicable diseases

385

1.96

7.10

1.0

8.88

8.81

mu/l

0.03

328

Other problems related to primary support group, including family circumstances

355

1.93

6.24

1.0

10.09

8.58

mu/l

0.86

309

Persons with potential health hazards related to socioeconomic and psychosocial circumstances

372

1.84

5.41

1.0

9.95

8.54

mu/l

0.78

316

Atopic dermatitis, strict definition

355

1.85

5.36

1.0

9.37

8.68

mu/l

0.32

292

Acute suppurative otitis media

250

1.98

5.16

1.0

9.65

8.19

mu/l

0.58

212

Vertebral, anorectal, cardiavascular, thracheoesophagial, renal and limb anomaly, including avohilmo

370

1.79

4.92

1.0

9.35

8.59

mu/l

0.36

321

Contact with and exposure to communicable diseases

344

1.83

4.90

1.0

9.24

8.78

mu/l

0.17

294

Vertebral, anorectal, cardiavascular, thracheoesophagial, renal and limb anomaly

372

1.78

4.82

1.0

9.35

8.59

mu/l

0.36

323

Suppurative and unspecified otitis media

256

1.87

4.47

1.0

10.64

8.20

mu/l

1.13

215

Respiratory and cardiovascular disorders specific to the perinatal period

361

1.74

4.19

1.0

11.76

8.25

mu/l

2.11

312

Diabetes mellitus in pregnancy

4.86

4.18

1.0

12.68

7.55

mu/l

—

Diarrhoea and gastroenteritis of presumed infectious origin

388

1.63

3.77

1.0

8.75

8.84

mu/l

0.04

327

Other maternal disorders predominantly related to pregnancy

4.28

3.77

1.0

14.10

6.78

mu/l

—

Diseases of middle ear and mastoid

256

1.72

3.47

1.0

10.61

8.20

mu/l

1.11

215

First line medication for Crohn's disease

314

0.51

3.30

1.0

10.81

8.62

mu/l

0.59

260

Dermatitis due to ingested food

258

1.76

3.30

1.0

8.90

8.79

mu/l

0.04

218

Congenital malformations of the circulatory system

372

1.62

3.28

1.0

10.27

8.60

mu/l

0.81

323

Certain conditions originating in the perinatal period

285

1.69

3.27

1.0

11.22

8.05

mu/l

1.73

243

Atopic dermatitis, strict definition with reimbursement

295

1.69

3.25

1.0

10.27

8.79

mu/l

0.69

237

Congenital malformations of heart and great arteries

373

1.62

3.24

1.0

10.21

8.59

mu/l

0.78

324

Other viral diseases, not elsewhere classified, including avohilmo

376

1.61

3.19

1.0

8.74

8.83

mu/l

0.04

317

Hard cardiovascular diseases

318

0.52

3.02

1.0

6.92

8.76

mu/l

1.48

271

Disorders of tooth development and eruption

248

1.68

3.01

1.0

9.37

8.92

mu/l

0.14

225

Ischemic heart diseases

295

0.50

2.97

1.0

6.84

8.68

mu/l

1.23

250

ILD medications

296

0.53

2.96

1.0

10.92

8.68

mu/l

0.55

237

Autoimmune diseases

356

0.58

2.91

1.0

9.56

8.98

mu/l

0.22

296

Major coronary heart disease event

294

0.51

2.91

1.0

6.84

8.67

mu/l

1.22

249

Emergency coronary revascularization (for ACS)

294

0.51

2.84

1.0

6.84

8.67

mu/l

1.22

249

Disorders of psychological development

348

1.58

2.81

1.0

8.45

8.82

mu/l

0.18

299

Coronary revascularization (ANGIO or CABG)

294

0.52

2.79

1.0

6.84

8.67

mu/l

1.22

249

Percutaneous Coronary Intervention

294

0.52

2.78

1.0

6.84

8.67

mu/l

1.22

249

Autoimmune diseases excluding thyroid diseases

312

0.56

2.77

1.0

10.06

9.32

mu/l

0.25

256

Gestational diabetes (for exclusion)

3.44

2.74

1.0

16.04

6.40

mu/l

—

Autoimmune diseases excluding thyroid diseases, strict definition

305

0.55

2.74

1.0

9.48

9.18

mu/l

0.10

250

Other viral diseases, including avohilmo

391

1.55

2.72

1.0

8.91

8.87

mu/l

0.02

324

Fever of other and unknown origin

224

1.66

2.55

1.0

9.87

8.35

mu/l

0.51

181

384

1.53

2.50

1.0

9.85

8.71

mu/l

0.56

321

Continuous positive airway pressure

284

1.56

2.41

1.0

11.27

8.48

mu/l

1.29

252

Persons encountering health services in circumstances related to reproduction

313

1.48

2.40

1.0

8.54

8.68

mu/l

0.06

274

Viral infections characterized by skin and mucous membrane lesions, including avohilmo

385

1.46

2.38

1.0

11.22

8.36

mu/l

1.68

320

Congenital malformations, deformations and chromosomal abnormalities, including avohilmo

277

1.58

2.36

1.0

9.83

8.68

mu/l

0.41

226

Nonsuppurative otitis media

237

1.61

2.34

1.0

9.83

8.25

mu/l

0.77

199

Respiratory distress of newborn

348

1.55

2.31

1.0

9.91

8.29

mu/l

0.95

308

Fall on same level

420

0.66

2.28

1.0

7.68

8.93

mu/l

0.94

355

Congenital malformations, deformations and chromosomal abnormalities

284

1.57

2.27

1.0

9.82

8.77

mu/l

0.37

231

Intestinal infectious diseases

390

1.43

2.26

1.0

8.71

8.88

mu/l

0.07

328

Congenital malformations of cardiac septa

370

1.50

2.25

1.0

9.78

8.60

mu/l

0.54

323

Asthma, hospital admission 2, infections

390

1.47

2.18

1.0

9.85

8.70

mu/l

0.57

327

Asthma-related infections

390

1.47

2.18

1.0

9.85

8.70

mu/l

0.57

327

Arthropathies

237

0.58

2.12

1.0

8.67

8.66

mu/l

0.00

191

ILD medications: prednisolone, methylprednisolone, prednisone

224

0.55

2.11

1.0

12.52

8.77

mu/l

0.77

179

Neoplasms

362

0.65

2.11

1.0

9.39

8.67

mu/l

0.23

314

Open wound of head

313

1.50

2.02

1.0

7.72

8.99

mu/l

1.06

269

Other viral infections characterized by skin and mucous membrane lesions, not elsewhere classified, including avohilmo

348

1.48

1.94

1.0

10.59

8.66

mu/l

0.98

295

Other joint disorders

191

0.55

1.93

1.0

8.71

9.08

mu/l

0.13

148

Delayed milestone in childhood

375

1.45

1.87

1.0

8.15

8.85

mu/l

0.41

327

Atopic dermatitis

304

1.44

1.81

1.0

10.26

8.79

mu/l

0.75

245

Used for control exclusion in common control thyroid runs

373

0.70

1.71

1.0

9.78

8.87

mu/l

0.45

312

Procreative management

292

1.44

1.69

1.0

9.06

8.62

mu/l

0.21

253

Childhood allergy (age < 16)

329

1.41

1.64

1.0

9.63

8.77

mu/l

0.41

268

Dentofacial anomalies [including malocclusion]

300

1.41

1.60

1.0

9.24

9.00

mu/l

0.12

246

Disorders of ocular muscles, binocular movement, accommodation and refraction

417

1.38

1.58

1.0

9.07

8.80

mu/l

0.13

349

Benign neoplasms

212

0.62

1.54

1.0

10.12

8.43

mu/l

0.31

178

Soft tissue disorders

364

0.72

1.52

1.0

6.82

9.28

mu/l

3.61

299

Hypertensive diseases (excluding secondary)

181

0.58

1.50

1.0

11.27

8.78

mu/l

0.79

151

Anomalies of dental arch relationship, including avohilmo

293

1.42

1.48

1.0

8.74

9.05

mu/l

0.13

245

Care involving use of rehabilitation procedures

329

1.39

1.48

1.0

10.61

8.59

mu/l

1.36

275

Nonsuppurative otitis media, including avohilmo

230

1.47

1.0

9.88

8.25

mu/l

0.56

192

Cardiovascular diseases (excluding rheumatic etc)

414

0.73

1.43

1.0

8.78

mu/l

0.00

349

Hypertension

173

0.59

1.43

1.0

11.27

8.76

mu/l

0.80

144

Hypertensive diseases

173

0.59

1.43

1.0

11.27

8.76

mu/l

0.80

144

Conjunctivitis (acute, non atopic)

370

1.37

1.39

1.0

8.38

8.81

mu/l

0.22

313

Pure hypercholesterolaemia

0.00

1.39

0.0

1.0

—

9.77

—

Vasomotor and allergic rhinitis

330

1.39

1.38

1.0

9.05

8.72

mu/l

0.12

268

Specific development disorders of speech and language

319

1.40

1.36

1.0

9.16

8.93

mu/l

0.09

276

Other disorders of ear

296

0.68

1.35

1.0

9.34

8.60

mu/l

0.34

257

Behavioural syndromes associated with physiological disturbances and physical factors

177

0.57

1.33

1.0

11.75

8.44

mu/l

1.05

146

Caries of enamel

350

1.31

1.32

1.0

7.49

9.03

mu/l

1.54

294

Speech and linguistic disorders, excluding more controls

291

1.39

1.26

1.0

9.34

8.61

mu/l

0.34

251

Sleep disorders

150

0.55

1.24

1.0

10.64

8.56

mu/l

0.52

121

Disorders of other endocrine glands

409

1.32

1.22

1.0

9.86

8.59

mu/l

0.40

347

Dental caries

239

1.42

1.21

1.0

8.21

8.86

mu/l

0.35

216

Cardiovascular diseases

415

0.77

1.21

1.0

8.86

8.81

mu/l

0.02

349

Other soft tissue disorders, not elsewhere classified

340

0.74

1.19

1.0

6.55

9.26

mu/l

4.16

278

Speech and linguistic disorders

367

1.34

1.19

1.0

9.21

8.82

mu/l

0.18

317

Heart failure,strict

0.44

1.16

1.0

13.31

8.13

mu/l

—

All-cause Heart Failure

0.43

1.15

1.0

13.31

8.13

mu/l

—

Heart failure, strict

0.43

1.15

1.0

13.31

8.13

mu/l

—

387

1.32

1.13

1.0

9.44

8.69

mu/l

0.31

336

Intracranial injury

312

1.34

1.11

1.0

9.00

9.09

mu/l

0.03

257

Allergic rhinitis

351

1.32

1.07

1.0

9.05

8.43

mu/l

0.24

289

Provisional assignment of new diseases of uncertain etiology

293

1.35

1.06

1.0

8.26

8.98

mu/l

0.37

253

Codes for special purposes

293

1.35

1.06

1.0

8.26

8.98

mu/l

0.37

253

Haemorrhagic and haematological disorders of fetus and newborn

351

1.33

1.05

1.0

8.94

8.83

mu/l

0.04

304

Episodal and paroxysmal disorders

399

0.79

1.04

1.0

9.10

8.89

mu/l

0.10

328

Insomnia

0.45

1.02

1.0

11.20

9.64

mu/l

—

Other and unspecified mental retardation

280

1.37

1.01

1.0

11.15

8.66

mu/l

1.51

248

Pain and other conditions associated with female genital organs and menstrual cycle

0.00

0.99

0.0

1.0

—

15.26

—

Conjunctivitis (acute, non atopic), including avohilmo

263

1.28

0.98

1.0

9.14

9.05

mu/l

0.03

216

Abdominal and pelvic pain

356

0.79

0.94

1.0

8.60

8.84

mu/l

0.11

296

Any reimbursement code in KELA

287

0.77

0.93

1.0

11.44

8.32

mu/l

1.30

236

STROKE

0.49

0.92

1.0

8.90

7.91

mu/l

—

Cerebrovascular diseases

0.54

0.90

1.0

8.83

8.67

mu/l

—

Asthma, hospital admissions , main diagnosis only

407

1.24

0.83

1.0

9.85

8.69

mu/l

0.56

338

Conjunctivitis

398

1.23

0.83

1.0

8.94

8.83

mu/l

0.04

328

Persons encountering health services in other circumstances

186

1.38

0.82

1.0

10.28

9.06

mu/l

0.34

148

Congenital malformations and deformations of the musculoskeletal system

326

1.28

0.82

1.0

8.34

8.79

mu/l

0.17

276

Diabetes, insulin treatment (Kela reimbursement)

106

0.62

0.80

1.0

7.92

8.61

mu/l

—

Presence of other devices

0.00

0.79

0.0

1.0

—

8.51

—

0.00

0.78

0.0

1.0

—

11.12

—

Congenital malformations and deformations of the musculoskeletal system, including avohilmo

337

1.27

0.78

1.0

8.28

8.73

mu/l

0.17

284

Viral infections of the central nervous system

2.08

0.74

1.0

6.43

8.42

mu/l

—

Viral infections of the central nervous system, including avohilmo

2.08

0.74

1.0

6.43

8.42

mu/l

—

Pollen allergy

328

1.26

0.74

1.0

9.24

8.70

mu/l

0.18

273

Behavioural and emotional disorders with onset usually occurring in childhood and adolescence

376

1.23

0.73

1.0

8.45

8.67

mu/l

0.12

312

Diabetes, insuline treatment (Kela reimbursement), excluding more controls

103

0.63

0.73

1.0

7.92

8.39

mu/l

—

Other strabismus

306

1.27

0.72

1.0

9.53

8.98

mu/l

0.20

254

Hypothyroidism (congenital or acquired)

117

0.67

0.72

1.0

10.42

8.79

mu/l

—

101

Other and unspecified tonsillitis

161

1.34

0.70

1.0

9.68

8.13

mu/l

0.53

124

Pneumonia, organism unspecified

372

1.20

0.69

1.0

11.49

8.32

mu/l

2.19

315

380

1.24

0.69

1.0

9.54

8.69

mu/l

0.32

329

Diarrhoea and gastroenteritis of presumed infectious origin, including avohilmo

354

1.19

0.68

1.0

8.30

8.94

mu/l

0.30

295

Neurological diseases

400

0.84

0.68

1.0

9.14

8.83

mu/l

0.15

333

Chronic lower respiratory diseases

396

0.84

0.67

1.0

9.79

8.71

mu/l

0.57

327

Pneumonia (excl. viral and due to other infectious organisms not elsewhere classified)

388

1.18

0.65

1.0

11.14

8.45

mu/l

1.82

326

GASTRO-related operations

337

0.83

0.64

1.0

9.92

8.42

mu/l

0.63

283

Any gastric operation

337

0.83

0.64

1.0

9.92

8.42

mu/l

0.63

283

Strabismus

313

1.24

0.63

1.0

9.53

9.04

mu/l

0.18

260

Meniscus derangement

0.00

0.62

0.0

1.0

—

5.71

—

Shoulder lesions

0.00

0.61

0.0

1.0

—

9.62

—

Erysipelas, including avohilmo

0.00

0.61

0.0

1.0

—

10.10

—

Other predominantly sexually transmitted diseases, not elsewhere classified, including avohilmo

0.00

0.60

0.0

1.0

—

8.70

—

Chronic sinusitis

0.00

0.60

0.0

1.0

—

6.78

—

Viral and other specified intestinal infections, including avohilmo

279

1.24

0.59

1.0

7.10

9.24

mu/l

2.30

224

Other headache syndromes

0.00

0.58

0.0

1.0

—

9.30

—

Pneumonias (Asthma/COPD co-morbidities)

392

1.17

0.57

1.0

10.64

8.44

mu/l

1.36

325

Neonatal jaundice from other and unspecified causes

345

1.22

0.57

1.0

8.16

8.77

mu/l

0.33

298

Motor disorders, excluding more controls

207

1.28

0.56

1.0

9.02

8.75

mu/l

0.08

174

Diabetes mellitus

127

0.73

0.56

1.0

11.54

8.69

mu/l

—

Cardiac murmurs and other cardiac sounds

236

1.26

0.55

1.0

6.77

9.04

mu/l

1.61

195

Diabetes, varying definitions

127

0.73

0.55

1.0

11.54

8.69

mu/l

—

Pain in limb

328

0.83

0.54

1.0

6.53

9.26

mu/l

4.02

269

Disorders of conjunctiva

398

1.17

0.53

1.0

8.90

8.83

mu/l

0.03

328

Autoimmune diseases related-to ILD

0.60

0.52

1.0

13.30

8.59

mu/l

—

All pneumoniae

394

1.15

0.52

1.0

10.64

8.44

mu/l

1.36

327

Persons with potential health hazards related to family and personal history and certain conditions influencing health status

396

1.15

0.51

1.0

9.81

8.64

mu/l

0.62

332

Headache

186

1.25

0.51

1.0

7.20

8.64

mu/l

0.78

143

Fetus and newborn affected by maternal factors and by complications of pregnancy, labour and delivery

349

1.21

0.51

1.0

9.15

8.62

mu/l

0.13

301

Other disorders starting during childhood or adolecense, excluding more controls

268

1.21

0.47

1.0

9.09

8.38

mu/l

0.29

232

Follow-up examination after treatment for conditions other than malignant neoplasms

0.59

0.47

1.0

5.76

10.02

mu/l

—

Symptoms and signs involving the digestive system and abdomen

373

0.87

0.46

1.0

9.19

8.75

mu/l

0.22

313

Influenza and pneumonia

391

1.14

0.45

1.0

10.55

8.34

mu/l

1.41

326

Disorders of skin appendages

0.58

0.45

1.0

8.18

8.84

mu/l

—

Diabetes medication

123

0.76

0.45

1.0

10.53

8.58

mu/l

—

Visual disturbances

209

0.77

0.45

1.0

8.75

8.69

mu/l

0.02

171

All kidney diseases

345

0.85

0.44

1.0

10.47

8.60

mu/l

0.74

289

Other disorders of skin and subcutaneous tissue

110

0.69

0.43

1.0

8.97

9.87

mu/l

—

Molar incisor enamel hypoplasia

307

1.19

0.43

1.0

9.92

8.90

mu/l

0.29

262

Feeding problems of newborn

1.38

0.43

1.0

10.75

8.59

mu/l

0.50

Viral and other specified intestinal infections

224

1.22

0.42

1.0

6.73

9.18

mu/l

2.50

175

Specific developmental disorder of motor function

224

1.23

0.42

1.0

9.02

9.14

mu/l

0.03

192

Disorders of the thyroid gland

135

0.77

0.42

1.0

10.09

9.69

mu/l

—

114

Injury, poisoning and certain other consequences of external causes

244

1.15

0.41

1.0

9.42

8.85

mu/l

0.23

207

Cardiac arrest

0.00

0.41

0.0

1.0

—

15.41

—

Asthma, including avohilmo

393

0.88

0.41

1.0

9.39

8.72

mu/l

0.33

325

Internal derangement of knee

0.00

0.41

0.0

1.0

—

10.63

—

Mandibular prognathia AND surgery (LeFortI or BSSO), including avohilmo

0.00

0.40

0.0

1.0

—

16.03

—

Congenital mitral valve regurgitation

0.00

0.40

0.0

1.0

—

11.71

—

Diseases of pulp and periapical tissues, including avohilmo

147

0.81

0.40

1.0

6.86

9.18

mu/l

1.62

106

Urticaria

259

1.20

0.40

1.0

7.07

9.24

mu/l

1.67

211

Mandibular prognathia

0.00

0.40

0.0

1.0

—

16.03

—

Other perinatal haematological disorders

1.42

0.39

1.0

12.81

8.93

mu/l

—

Major anomalies of jaw size

0.00

0.39

0.0

1.0

—

16.03

—

Impacted maxillary molar

0.00

0.39

0.0

1.0

—

16.21

—

Vaginitis/vulvovaginitis/vulvitis/abscess of vulva

0.00

0.39

0.0

1.0

—

7.02

—

Fracture of foot, except ankle

0.00

0.39

0.0

1.0

—

11.96

—

Injuries to the head

364

1.12

0.39

1.0

8.16

9.00

mu/l

0.55

304

Persons encountering health services in other circumstances, wide

315

1.13

0.39

1.0

10.21

8.71

mu/l

0.70

265

Mastocytosis

1.40

0.38

1.0

5.17

8.44

mu/l

—

Other fall from one level to another

233

1.20

0.38

1.0

11.47

8.77

mu/l

0.88

195

Other congenital malformations of tongue, mouth and pharynx, including avohilmo

206

1.21

0.36

1.0

10.64

8.72

mu/l

0.82

185

Hypothyroidism, other/unspecified

126

0.78

0.36

1.0

10.09

9.61

mu/l

—

107

Anisometropia and aniseikonia

1.27

0.36

1.0

9.78

9.72

mu/l

—

Impacted cerumen

0.65

0.35

1.0

8.70

8.65

mu/l

—

Atopic conjunctivitis

1.40

0.35

1.0

14.21

8.16

mu/l

—

Accidents

272

1.12

0.34

1.0

8.94

8.92

mu/l

0.01

230

Concussion

320

1.14

0.34

1.0

8.76

8.84

mu/l

0.03

258

Visual disturbances and blindness

265

0.83

0.34

1.0

10.08

8.81

mu/l

0.55

220

Other and unspecified drugs and medicaments

1.33

0.33

1.0

9.41

7.92

mu/l

—

Hypothyroidism, strict autoimmune, 3 medication purchases required

0.75

0.33

1.0

7.03

9.94

mu/l

—

Conduction disorders

0.67

0.33

1.0

8.43

9.40

mu/l

—

Urticaria and erythema

295

1.15

0.31

1.0

7.36

9.03

mu/l

1.19

245

Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified

1.21

0.31

1.0

11.20

7.79

mu/l

0.95

Amblyopia ex anopsia

164

0.79

0.30

1.0

7.98

8.54

mu/l

0.21

143

External causes of morbidity and mortality

256

1.12

0.30

1.0

9.03

9.00

mu/l

0.01

217

Other diseases of upper respiratory tract

379

0.91

0.30

1.0

8.64

8.90

mu/l

0.11

315

Other congenital malformations of tongue, mouth and pharynx

156

1.22

0.30

1.0

9.45

8.49

mu/l

0.46

138

Symptoms and signs involving the nervous and musculoskeletal systems

287

1.15

0.29

1.0

9.53

9.15

mu/l

0.10

231

Tonsillectomy and adenotomy

397

1.10

0.29

1.0

9.78

8.84

mu/l

0.46

332

Left ventricular outflow tract obstruction (LVOTO), broad definition

130

0.77

0.29

1.0

7.65

9.21

mu/l

—

121

Asthma (diagnoses ohter than nonallergic)

385

1.11

0.28

1.0

8.85

8.98

mu/l

0.04

315

Diseases of the musculoskeletal system and connective tissue

379

0.91

0.28

1.0

7.60

9.13

mu/l

1.76

317

Implicit Sepsis, including avohilmo

269

0.88

0.28

1.0

8.22

9.12

mu/l

0.51

217

Asthma/COPD (KELA code 203)

371

0.90

0.28

1.0

9.86

8.72

mu/l

0.50

303

Other external causes of accidental injury

272

1.10

0.27

1.0

8.98

8.92

mu/l

0.02

230

Certain infectious and parasitic diseases, including avohilmo

210

1.12

0.27

1.0

10.26

8.59

mu/l

0.68

173

Motor disorders

241

1.16

0.27

1.0

9.02

8.85

mu/l

0.05

209

Condition for Implicit Sepsis (Organ dysfunction codes)

275

0.88

0.27

1.0

8.61

9.12

mu/l

0.23

224

Viral infections characterized by skin and mucous membrane lesions

289

1.14

0.27

1.0

10.62

8.71

mu/l

0.70

230

Infections of the skin and subcutaneous tissue

378

1.12

0.27

1.0

11.06

8.53

mu/l

0.92

316

Other disorders of adrenal gland

1.23

0.27

1.0

10.28

9.92

mu/l

—

Down's syndrome

0.68

0.27

1.0

16.88

8.71

mu/l

—

Invasive ventilation

128

0.78

0.26

1.0

10.49

9.18

mu/l

—

104

Any death

0.69

0.26

1.0

13.74

8.75

mu/l

—

Acute upper respiratory infections

173

1.14

0.26

1.0

12.35

8.03

mu/l

1.48

135

Endocrine, nutritional and metabolic diseases

372

1.09

0.26

1.0

9.80

8.58

mu/l

0.53

319

Persons encountering health services for other counselling and medical advice, not elsewhere classified

315

1.10

0.26

1.0

9.77

8.71

mu/l

0.44

265

Hypoplasia of dental enamel , including avohilmo

243

1.15

0.26

1.0

8.98

9.33

mu/l

0.12

201

Diseases of the skin and subcutaneous tissue

257

0.90

0.26

1.0

9.51

8.91

mu/l

0.23

206

Foreign body in respiratory tract

0.70

0.26

1.0

6.92

9.57

mu/l

—

Crossbite

243

1.14

0.24

1.0

9.55

8.88

mu/l

0.23

193

Chronic suppurative otitis media

1.26

0.24

1.0

6.71

8.45

mu/l

0.92

Insulin, combination of fast acting with intermediate-acting or long-acting

112

1.21

0.24

1.0

8.83

8.57

mu/l

—

Weight loss

0.71

0.24

1.0

9.54

9.43

mu/l

—

Other symptoms and signs involving the nervous and musculoskeletal systems

208

1.15

0.23

1.0

8.62

9.47

mu/l

0.34

167

Hypothyreosis and Thyroxine purchase for inclusion criteria

125

0.84

0.23

1.0

10.09

9.60

mu/l

—

106

Fracture of femur

1.33

0.23

1.0

10.66

7.89

mu/l

—

Ankyloglossia

199

1.16

0.23

1.0

10.37

9.23

mu/l

0.38

178

Symptoms and signs involving the urinary system

223

0.88

0.22

1.0

8.15

8.59

mu/l

0.19

191

Cerebral palsy

1.27

0.22

1.0

13.32

9.37

mu/l

—

Uterine polyps

0.00

0.22

0.0

1.0

—

Polyp of the female genital tract

0.00

0.22

0.0

1.0

—

Congenital obstructive defects of renal pelvis and congenital malformations of ureter

1.22

0.22

1.0

10.84

9.78

mu/l

—

Autism spe, excluding more controls

1.22

0.22

1.0

12.04

7.89

mu/l

—

Maxillary hypoplasia

0.00

0.21

0.0

1.0

—

18.40

—

Autism

1.19

0.21

1.0

12.04

8.84

mu/l

—

Drug-induced polyneuropathy

0.00

0.21

0.0

1.0

—

9.83

—

Leukaemia of unspecified cell type

0.00

0.21

0.0

1.0

—

6.70

—

Chronic diseases of tonsils and adenoids

357

0.92

0.21

1.0

9.02

8.87

mu/l

0.05

294

Other infective otitis externa

0.00

0.21

0.0

1.0

—

18.40

—

Pulmonary heart disease

0.00

0.21

0.0

1.0

—

14.44

—

Pulmonary embolism

0.00

0.21

0.0

1.0

—

14.44

—

Diseases of the digestive system

218

1.14

0.21

1.0

10.49

8.29

mu/l

0.67

189

DVT of lower extremities and pulmonary embolism

0.00

0.21

0.0

1.0

—

12.98

—

Combined immunodeficiencies

0.00

0.21

0.0

1.0

—

12.38

—

Kela-code for severe mental illness

0.00

0.21

0.0

1.0

—

7.30

—

Congenital malformations of pulmonary and tricuspid valves

113

0.79

0.20

1.0

8.08

8.33

mu/l

—

102

Residual foreign body in soft tissue

0.00

0.20

0.0

1.0

—

13.85

—

Disturbances of skin sensation

0.00

0.20

0.0

1.0

—

7.30

—

Other endocrine disorders

358

1.10

0.20

1.0

10.59

8.45

mu/l

0.55

310

Liquid cancers, including Hilmo

0.81

0.20

1.0

6.87

7.77

mu/l

—

Condition for Implicit Sepsis (Organ dysfunction codes), including avohilmo

296

0.91

0.19

1.0

9.18

8.89

mu/l

0.11

241

Mild mental retardation

1.20

0.19

1.0

12.93

9.74

mu/l

—

Right ventricular outflow tract obstruction

122

0.81

0.19

1.0

7.99

8.69

mu/l

—

107

Injuries to the ankle and foot

231

0.89

0.19

1.0

9.83

8.82

mu/l

0.20

185

Hypothyroidism, strict autoimmune

0.83

0.18

1.0

7.04

9.91

mu/l

—

Cerebral palsy and other paralytic syndromes

100

1.20

0.18

1.0

12.22

8.96

mu/l

0.83

Other disorders of fluid, electrolyte and acid-base balance

1.14

0.17

1.0

16.13

7.05

mu/l

—

Injury of eye and orbit

1.18

0.16

1.0

8.09

9.04

mu/l

—

Nonorganic sleeping disorders

120

0.83

0.16

1.0

10.99

8.50

mu/l

—

104

1.19

0.16

1.0

11.42

8.91

mu/l

—

Other respiratory disorders and diseases

130

0.85

0.16

1.0

8.63

8.77

mu/l

0.04

122

Other diseases of the respiratory system

130

0.85

0.16

1.0

8.63

8.77

mu/l

0.04

122

Agranulocytosis

1.10

0.15

1.0

7.51

8.23

mu/l

—

Psychiatric diseases

320

0.94

0.15

1.0

8.20

8.63

mu/l

0.24

271

Disorder of the sleep-wake schedule

0.75

0.15

1.0

11.35

8.36

mu/l

—

Dermatitis and eczema

305

1.07

0.15

1.0

10.32

8.79

mu/l

0.83

245

Coarctation of the aorta

0.81

0.14

1.0

8.40

8.89

mu/l

—

Other diseases of blood and blood-forming organs, wide

1.08

0.14

1.0

7.75

8.34

mu/l

—

Genitourinary diseases

370

0.95

0.13

1.0

10.29

8.55

mu/l

0.85

310

Purpura and other haemorrhagic conditions

0.83

0.13

1.0

8.85

9.21

mu/l

—

Other special examinations and investigations of persons without complaint or reported diagnosis

144

1.09

0.13

1.0

9.90

9.03

mu/l

0.34

112

Constipation

384

1.06

0.13

1.0

8.55

8.89

mu/l

0.18

325

Any mental disorder

322

0.95

0.12

1.0

8.20

8.63

mu/l

0.24

272

General symptoms and signs

231

1.06

0.12

1.0

9.52

8.43

mu/l

0.46

184

Persons encountering health services for specific procedures and health care

388

1.05

0.12

1.0

10.30

8.74

mu/l

1.09

326

Enterobiasis, including avohilmo

124

1.13

0.11

1.0

8.00

8.03

mu/l

0.01

109

Caries of dentine, including avohilmo

343

0.95

0.11

1.0

8.27

8.93

mu/l

0.35

296

Other diseases of hard tissues of teeth

263

0.94

0.11

1.0

9.99

8.72

mu/l

0.44

239

Gastrointestinal diseases

285

0.95

0.11

1.0

10.22

8.89

mu/l

0.49

234

Nonorganic sleeping disorders, excluding more controls

115

0.87

0.10

1.0

10.99

8.24

mu/l

—

100

Helminthiases, including avohilmo

125

1.12

0.10

1.0

8.00

8.06

mu/l

0.02

110

Abnormal serum enzyme levels

1.15

0.10

1.0

9.74

9.63

mu/l

—

Viral warts, including avohilmo

135

1.11

0.09

1.0

8.56

8.74

mu/l

—

108

Rash and other nonspecific skin eruption

1.06

0.09

1.0

6.34

9.60

mu/l

—

Insulin medication

112

1.11

0.09

1.0

8.83

8.57

mu/l

—

Autism spe

1.04

0.09

1.0

12.04

8.25

mu/l

—

Other perinatal digestive system disorders

1.10

0.09

1.0

7.03

8.96

mu/l

—

COPD/asthma/ILD related pneumonia or pneumonia derived septicaemia

147

1.07

0.09

1.0

9.29

8.12

mu/l

0.23

113

147

1.07

0.09

1.0

9.29

8.12

mu/l

0.23

113

Other diseases of intestines

404

0.96

0.08

1.0

8.37

8.94

mu/l

0.34

334

Acute lymphocytic leukaemia, helper endpoint

0.79

0.08

1.0

5.55

7.75

mu/l

—

Acute lymphocytic leukaemia, including Hilmo

0.79

0.08

1.0

5.55

7.75

mu/l

—

Acute lymphocytic leukaemia

0.79

0.08

1.0

5.55

7.75

mu/l

—

Digestive system disorders of fetus and newborn

1.10

0.08

1.0

6.59

8.67

mu/l

—

Dental operations

258

0.96

0.08

1.0

10.21

8.39

mu/l

0.74

227

Symptoms and signs concerning food and fluid intake

117

1.11

0.08

1.0

8.07

8.85

mu/l

0.30

101

Thrombocytopenia, unspecified

0.86

0.07

1.0

10.55

9.24

mu/l

—

Dental caries, including avohilmo

326

1.04

0.07

1.0

8.28

9.08

mu/l

0.48

285

Interstitial emphysema and related conditions originating in the perinatal period

1.06

0.07

1.0

13.88

7.83

mu/l

—

Open wound of wrist and hand

1.06

0.07

1.0

9.04

8.78

mu/l

—

Insulin, fast-acting

108

1.11

0.07

1.0

7.80

8.59

mu/l

—

Generalized epilepsy, strict definition

1.02

0.07

1.0

7.35

8.77

mu/l

—

Pain (limb, back, neck, head abdominally)

331

0.97

0.06

1.0

8.32

9.05

mu/l

0.42

279

Intestinal stricture

102

0.88

0.06

1.0

8.16

7.87

mu/l

—

Insulin, fast-acting or short human

109

1.10

0.06

1.0

7.80

8.62

mu/l

—

Exposure to unspecified factor

403

1.03

0.05

1.0

8.67

8.76

mu/l

0.03

334

Other and unspecified iron deficiency

139

1.08

0.05

1.0

7.18

8.43

mu/l

0.53

111

Intracranial trauma

321

0.97

0.05

1.0

8.97

8.84

mu/l

0.04

258

Bacterial Sepsis

107

0.93

0.04

1.0

10.16

8.63

mu/l

0.39

Other congenital malformations

311

0.96

0.04

1.0

6.84

8.79

mu/l

1.38

265

Congenital malformations of eyelid, lacrimal apparatus and orbit

121

1.08

0.03

1.0

6.99

8.35

mu/l

0.48

113

Other congenital malformations, including avohilmo

321

0.96

0.03

1.0

6.84

8.88

mu/l

1.48

273

Other disorders starting during childhood or adolescence

347

0.97

0.03

1.0

9.09

8.66

mu/l

0.16

306

Cardiovascular disorders originating in the perinatal period

128

0.93

0.03

1.0

14.01

7.38

mu/l

1.00

119

Symptoms and signs involving the circulatory and respiratory systems

307

0.98

0.03

1.0

9.77

8.99

mu/l

0.35

250

Certain infectious and parasitic diseases

319

1.02

0.03

1.0

9.22

8.63

mu/l

0.23

266

Implicit bacterial Sepsis, including avohilmo

0.92

0.03

1.0

11.48

8.45

mu/l

—

Diseases of pulp and periapical tissues and dental caries

322

1.02

0.02

1.0

8.34

9.11

mu/l

0.45

282

Excessive attrition of teeth

156

0.95

0.02

1.0

11.67

8.53

mu/l

—

118

Diseases of oral cavity, salivary glands and jaws

273

1.02

0.02

1.0

10.40

8.69

mu/l

0.79

249

Intestinal infectious diseases, including avohilmo, including avohilmo

345

1.02

0.02

1.0

8.38

8.99

mu/l

0.27

289

Falls/tendency to fall

370

0.99

0.01

1.0

8.78

8.80

mu/l

0.01

313

Diseases of the ear and mastoid process

247

1.01

0.00

1.0

10.85

8.15

mu/l

1.14

207

Anxiety disorders

0.98

0.00

1.0

7.04

10.09

mu/l

—

160

1.01

0.00

1.0

10.74

8.10

mu/l

1.07

124

Diseases of the eye and adnexa

328

0.99

0.00

1.0

8.54

8.64

mu/l

0.05

269

Implicit bacterial Sepsis

0.97

0.00

1.0

11.48

8.49

mu/l

—

COPD/asthma related infections

147

0.99

0.00

1.0

10.58

8.12

mu/l

0.92

113

COPD/asthma/ILD related infections

147

0.99

0.00

1.0

10.58

8.12

mu/l

0.92

113

Persons encountering health services for examination and investigation

144

1.01

0.00

1.0

12.31

9.03

mu/l

1.20

112

Viral pneumonia

105

0.95

0.00

1.0

9.12

7.90

mu/l

—

Other diseases of lip and oral mucosa

101

0.99

0.00

1.0

11.55

8.87

mu/l

—

Crowding of teeth, including avohilmo

202

0.98

0.00

1.0

9.97

8.86

mu/l

0.47

150

Neurotic, stress-related and somatoform disorders

0.98

0.00

1.0

7.04

10.09

mu/l

—

Other behavioural and emotional disorders with onset usually occurring in childhood and adolescence

333

1.00

0.00

1.0

9.09

8.61

mu/l

0.18

293

Coagulation defects, purpura and other haemorrhagic conditions

117

1.03

0.00

1.0

8.23

8.89

mu/l

0.16

102

Congenital malformations of eyelid, lacrimal apparatus and orbit, including avohilmo

135

1.04

0.00

1.0

6.96

8.44

mu/l

0.59

123

Short stature, not elsewhere classified

332

1.00

0.00

1.0

11.25

8.43

mu/l

0.68

286

Chronic respiratory disease originating in the perinatal period

0.91

0.00

1.0

7.29

7.35

mu/l

—

Congenital malformations of larynx

0.98

0.00

1.0

12.86

8.58

mu/l

—

Viral pneumonia (known virus, not influenza)

0.88

0.00

1.0

9.76

8.68

mu/l

—

Injuries to the hip and thigh

1.01

0.00

1.0

9.58

8.89

mu/l

—

Monosomies and deletions from the autosomes, not elsewhere classified

0.90

0.00

1.0

6.53

8.74

mu/l

—

Generalized epilepsy, mode (most common among epilepsy diagnosis)

0.95

-0.00

1.0

8.00

9.33

mu/l

—

Disorders of fatty-acid metabolism

0.00

-0.00

0.0

1.0

—

7.12

—

Visual impairment including blindness (binocular or monocular)

1.00

-0.00

1.0

12.99

8.62

mu/l

—

Hypertension, Pulmonary Arterial

0.00

-0.00

0.0

1.0

—

7.53

—

Infections, IBD-co-morbidities

1.00

-0.00

1.0

9.56

8.78

mu/l

—

Cholangitis (primary sclerosing, PSC)

0.90

-0.00

1.0

12.57

8.94

mu/l

—

Acute alcohol intoxication

0.00

-0.00

0.0

1.0

—

Other local infections of skin and subcutaneous tissue

0.87

-0.00

1.0

6.53

8.33

mu/l

—

Amputation of thigh

0.00

-0.00

0.0

1.0

—

8.57

—

Other and unspecified local infections of skin and subcutaneous tissue

0.87

-0.00

1.0

6.53

8.33

mu/l

—

Generalized pustular psoriasis

0.00

-0.00

0.0

1.0

—

8.91

—

Fetal blood loss

0.00

-0.00

0.0

1.0

—

8.14

—

Other disturbances of cerebral status of newborn

1.03

-0.00

1.0

16.10

8.72

mu/l

—

Hypothermia of newborn

0.00

-0.00

0.0

1.0

—

6.09

—

Nanophthalmos, microphthalmos and macrophthalmos

0.00

-0.00

0.0

1.0

—

5.32

—

Congenital lactase deficiency

0.00

-0.00

0.0

1.0

—

5.17

—

Congenital nasolacrimal duct obstruction or stenosis, including avohilmo

0.99

-0.00

1.0

7.91

8.47

mu/l

—

Other specified disorders of external ear

0.00

-0.00

0.0

1.0

—

8.57

—

Congenital nasolacrimal duct obstruction or stenosis

1.00

-0.00

1.0

8.09

8.34

mu/l

—

Foreign body entering into or through eye or natural orifice

1.02

-0.00

1.0

8.08

9.67

mu/l

—

Other disorders of glucose regulation and pancreatic internal secretion

1.01

-0.00

1.0

7.24

9.33

mu/l

—

Disorders of branched-chain amino-acid metabolism and fatty-acid metabolism

0.00

-0.00

0.0

1.0

—

7.32

—

Disorders of ornithine metabolism

0.00

-0.00

0.0

1.0

—

8.57

—

Other congenital malformations of posterior segment of eye (coloboma)

0.00

-0.00

0.0

1.0

—

5.70

—

Disorders of urea cycle metabolism

0.00

-0.00

0.0

1.0

—

8.57

—

Keratitis

0.97

-0.00

1.0

12.02

8.64

mu/l

—

Severe visual impairment, monocular

0.00

-0.00

0.0

1.0

—

9.01

—

Generalized epilepsy

0.96

-0.00

1.0

7.35

8.95

mu/l

—

≡ Risteys

R14

FinnGen R13 + FinRegistry

FinnGen R12 + FinRegistry

FinnGen R11 + FinRegistry

FinnGen R10 + FinRegistry

FinnGen R10

FinnGen R9

FinnGen R8

FinnGen R7

FinnGen R6

FinnGen R5

FinnGen R4

FinnGen R3

Thyrotropin [Units/volume] in Cord blood

Coding

Definition

OMOP mapping QC

Cohort

Year of birth distribution

Age at first measurement

Age at last measurement

Age at start of registry

Duration from first to last measurement

Statistics

Number of measurements over the years

Number of measurements per person

Distribution of lab values

Value range per person

LabWAS